Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Dyslipidaemias in 2017

Atherogenic lipoproteins as treatment targets

Nature Reviews Cardiology volume 15, pages 75–76 (2018)Cite this article

Subjects

Research on dyslipidaemias in 2017 reaffirmed the central role of reducing the levels of atherogenic apolipoprotein B-containing lipoproteins, predominantly LDL, in preventing ischaemic cardiovascular events. However, whether increasing HDL-cholesterol levels in isolation can reduce cardiovascular risk remains to be determined.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches.

References

  1. Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R. & Tybjaerg-Hansen, A. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study. BMJ 357, j1648 (2017).

    Article  Google Scholar 

  2. Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017).

    Article  CAS  Google Scholar 

  3. Giugliano, R. P. et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 390, 1962–1971 (2017).

    Article  CAS  Google Scholar 

  4. Wang, S. et al. Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis. Sci. Rep. 7, 39982 (2017).

    Article  CAS  Google Scholar 

  5. Vallejo-Vaz, A. J. et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation 136, 1878–1891 (2017).

    Article  CAS  Google Scholar 

  6. Shepherd, J. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333, 1301–1307 (1995).

    Article  CAS  Google Scholar 

  7. Ray, K. K. et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med. 376, 1430–1440 (2017).

    Article  CAS  Google Scholar 

  8. Galabova, G. et al. Peptide-based anti-PCSK9 vaccines — an approach for long-term LDLc management. PLoS ONE 9, e114469 (2014).

    Article  Google Scholar 

  9. Landlinger, C. et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden. CETP mice. Eur. Heart J. 38, 2499–2507 (2017).

    Article  CAS  Google Scholar 

  10. Bowman, L. et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N. Engl. J. Med. 377, 1217–1227 (2017).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Alberico L. Catapano is at the Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy,

    Alberico L. Catapano

  2. IRCCS MultiMedica, Sesto S. Giovanni, Via Milanese 100, 20099 Milan, Italy.,

    Alberico L. Catapano

Authors
  1. Alberico L. Catapano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberico L. Catapano.

Ethics declarations

Competing interests

A.L.C. received research funding and honoraria as a speaker or consultant for Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Mediolanum, Merck, Pfizer, Recordati, Rottapharm, Sanofi-Regeneron, and Sigma-Tau.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Catapano, A. Atherogenic lipoproteins as treatment targets. Nat Rev Cardiol 15, 75–76 (2018). https://doi.org/10.1038/nrcardio.2017.221

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2017.221

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing